Prevalence and geographical variation of dementia in New Zealand (NZ) from 2012-2015: Brief report utilising routinely collected data within the Integrated Data Infrastructure (IDI) by Walesby, Katherine et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prevalence and geographical variation of dementia in New
Zealand (NZ) from 2012-2015: Brief report utilising routinely
collected data within the Integrated Data Infrastructure (IDI)
Citation for published version:
Walesby, K, Exeter, DJ, Gibb, S, Wood, P, Starr, J & Russ, T 2020, 'Prevalence and geographical variation
of dementia in New Zealand (NZ) from 2012-2015: Brief report utilising routinely collected data within the
Integrated Data Infrastructure (IDI)', Australasian Journal on Ageing. https://doi.org/10.1111/ajag.12790
Digital Object Identifier (DOI):
10.1111/ajag.12790
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Australasian Journal on Ageing
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 21. Jun. 2020
Australas J Ageing. 2020;00:1–8.    | 1wileyonlinelibrary.com/journal/ajag
Received: 20 June 2019 | Revised: 17 February 2020 | Accepted: 18 February 2020
DOI: 10.1111/ajag.12790  
B R I E F  R E P O R T
Prevalence and geographical variation of dementia in New 
Zealand from 2012 to 2015: Brief report utilising routinely 
collected data within the Integrated Data Infrastructure
Katherine Elizabeth Walesby1,2  |   Daniel John Exeter3  |   Sheree Gibb4 |    
Philip Clive Wood5,6,7 |   John Michael Starr1,8* |   Tom Charles Russ1,2,9,10,11
1Alzheimer Scotland Dementia Research Centre, University of Edinburgh, Edinburgh, UK
2Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK
3Epidemiology and Biostatistics, School of Population Health, University of Auckland, Auckland, New Zealand
4Department of Public Health, University of Otago, Wellington, New Zealand
5North Shore Hospital, Auckland, New Zealand
6Auckland Dementia Prevention Research Clinic, Auckland, New Zealand
7Healthy Ageing, Ministry of Health New Zealand, Wellington, New Zealand
8Western General Hospital, NHS Lothian, Edinburgh, UK
9Centre for Dementia Prevention, University of Edinburgh, Edinburgh, UK
10Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
11NHS Lothian, Edinburgh, UK
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2020 The Authors. Australasian Journal on Ageing published by John Wiley & Sons Australia, Ltd on behalf of AJA Inc
Daniel John Exeter and Sheree Gibb joint second authors. 
‡Deceased. 
Correspondence
Katherine Elizabeth Walesby, Alzheimer 
Scotland Dementia Research Centre, 7 
George Square, University of Edinburgh, 
EH8 9JZ Edinburgh, UK.
Email: Katherine.walesby@ed.ac.uk
Funding information
Medical Research Council (MRC) UK, 
Grant/Award Number: MR/L501530/1 
and MR/K02992/1; Medical Research 
Council Supplementary Travel Grant; 
Biotechnology and Biological Sciences 
Research Council; Alzheimer Scotland, 
Grant/Award Number: R44394
Abstract
Objectives: There are no national dementia epidemiological studies using New 
Zealand (NZ) data. NZ routinely collects health-care data within the Integrated Data 
Infrastructure (IDI). The study objectives were to 1) investigate late-onset dementia 
estimates using the IDI between 2012-2015 and compare these with 2) published 
estimates, and 3) variations between North and South Islands and ethnicity.
Methods: A population-based, retrospective cohort design was applied to routinely 
collected de-identified health/administrative IDI data. Dementia was defined by 
ICD-10-AM dementia codes or anti-dementia drugs.
Results: Approximately 2% of those aged ≥60 years had dementia, lower than pub-
lished estimates. Dementia was higher in North Island; in 80- to 89-year-olds; among 
the Māori population when age-standardised, and 9% of all dementia cases had >1 
dementia sub-type.
Conclusions: To our knowledge, this is the first study ascertaining dementia esti-
mates using NZ's whole-of-population IDI data. Estimates were lower than existing 
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1 |  INTRODUCTION
Dementia is an important public health concern, predicted to 
affect 75.62 million people worldwide in 2030.1 Understanding 
country-specific burden of disease facilitates effective health-
care delivery. There have been no national New Zealand (NZ) 
epidemiological studies of dementia.2-4 One valuable study 
(LiLACS NZ) investigated dementia prevalence using NZ 
data but not at a national level.5,6 LiLACS NZ uses a small 
population within two districts of North Island and focuses 
on the older age groups (≥80-year-old Māori and ≥85-year-
old Non-Māori).5,6 However, estimates for national dementia 
prevalence have previously been produced by applying demen-
tia prevalence rates for Australia to the estimated population 
of NZ3,4 or by using incidence rates for Alzheimer dementia 
from an international systematic review modelled on NZ's age-
ing population.2 The Alzheimer Disease International (ADI) 
2015 report produced regional (Australasian) dementia preva-
lence estimates. Therefore, the recent NZ estimates apply the 
Australian prevalence rates to the United Nations projections 
for NZ's population.4 Given the diverse ethnic compositions 
of NZ and Australia, we contend that whilst these ADI reports 
are useful, they are unlikely to accurately reflect the situation 
of NZ. Variations in dementia prevalence between and within 
countries are well recognised,7,8 including dementia mortality 
differences between NZ's North and South Islands.7
Greater information on dementia prevalence in NZ is re-
quired, and NZ's linked health and administrative population 
data within the Integrated Data Infrastructure (IDI)9 provide 
some data to study dementia at a population level. The IDI, a 
large research database containing microdata about people and 
households,9 contains mortality, medication dispensing and hos-
pital discharge data sets necessary to ascertain dementia, using 
methods similar to in previous international research.8,10-12
The aims of this study were to: (a) investigate NZ's late-on-
set dementia prevalence using the IDI for 2012 to 2015 (in-
clusive); (b) compare this with published NZ estimates; and 
(c) compare variations between the North and South Islands 
and by ethnicity.
2 |  METHODS
A population-based retrospective cohort study was used 
analysing routinely collected de-identified health and 
administrative data stored within NZ's IDI system. Health 
data comprised Primary Health Organisation; publicly 
funded hospital discharges (National Minimum Dataset 
[NMDS]); subsidised dispensing (Ministry of Health [MOH] 
and Pharmaceutical Management Agency [PHARMAC]); 
and mortality, cause of death, data (MOH). Other administra-
tive data comprised Inland Revenue (pensions) and Accident 
Compensation Corporation (ACC) data sets.
2.1 | Data access, linkage and cohorts
Data were stored securely by Statistics NZ, with access 
granted following approvals.9
The IDI October 2016 version (Appendix S1) was used to 
create annual cohorts for 2012-2015. Our population at risk 
of dementia (denominator) was defined within the IDI as all 
individuals aged ≥60 years (alive or died during the year) and 
NZ residents who had interacted with any of the health data 
sets above, Inland Revenue (pensions) or ACC data sets. Our 
numerator therefore represented those individuals defined as 
having dementia in that year. We also obtained age, sex and 
multi-response ethnicity.13,14
For each year, dementia cases (numerators) were counted 
using the case definition of dementia. Using SAS and SQL, 
the cohort was linked to health data sets (NMDS, dispensing 
and mortality data).
2.2 | Dementia ascertainment
Dementia was defined by any mention of ICD-10-AM 
(Australian modification version) dementia codes in NMDS 
or mortality data sets; or anti-dementia drug prescriptions in 
NZ estimates, for several reasons. Further work is required, including expanding IDI 
data sets, to develop future estimates that better reflect NZ's diverse population.
K E Y W O R D S
Dementia, epidemiology, New Zealand, prevalence
Policy Impact
This research highlights discrepancies between es-
timates of New Zealand (NZ) dementia prevalence 
and those within the Integrated Data Infrastructure, 
emphasising the need for a more detailed epidemio-
logical study within NZ to provide country-specific 
dementia data to help guide health care and policies.
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T A B L E  1  Dementia prevalence, dementia sub-types and demographics for the cohorts 2012-2015
Study population—population ≥60 years in NZ per year 
(denominator group, population at risk) 2012 2013 2014 2015
Total people per year ≥60 years old in NZ 891 558 916 065 945 252 966 483
Sex (% of total study population)a 
Male 409 173 (46%) 422 199 (46%) 436 506 (46%) 446 574 (46%)
Female 474 429 (53%) 487 983 (53%) 502 815 (53%) 513 975 (53%)
Ethnicityb 
Māori 59 145 62 208 65 508 68 670
Pacific 25 572 26 562 27 957 29 100
European 742 536 761 670 781 581 794 670
Asian 44 076 47 982 52 320 56 073
Middle Eastern, Latin American and African (MELAA) 2820 3042 3336 3627
Other 13 602 14 607 15 477 16 137
Age rangea 
60-64 234 312 237 288 242 226 242 553
65-69 201 471 214 593 224 991 231 792
70-74 159 402 162 735 167 277 171 084
75-79 114 567 118 638 123 531 131 064
80-84 88 539 88 965 90 126 90 180
85-89 55 209 56 601 58 026 59 397
90-94 23 409 24 549 26 139 26 802
95+ 6696 6819 7002 7680
Total people by North/South Islandc 
North Island 637 245 660 852 683 220 699 813
South Island 230 001 237 825 244 248 248 934
Dementia prevalence
All dementia cases—numerator (% of total study population) 13 677 (2%) 13 155 (1%) 13 800 (2%) 14 391 (2%)
Dementia by sub-type: (% of total dementia cases per year)
Alzheimer dementia 2499 (18%) 2094 (16%) 2142 (16%) 2166 (15%)
Vascular dementia 1257 (9%) 1284 (10%) 1338 (10%) 1407 (10%)
Parkinson's disease dementia 447 (3%) 432 (3%) 441 (3%) 447 (3%)
Other (including unspecified dementia sub-type) dementia 10 647 (78%) 10 563 (80%) 11 166 (81%) 11 736 (82%)
More than one type of dementia 1110 (8%) 1140 (9%) 1194 (9%) 1272 (9%)
Dementia by sex
Male (% of total study population per year) 5418 (1%) 5601 (1%) 5856 (1%) 6240 (1%)
Female (% of total study population per year) 8091 (1%) 7542 (1%) 7935 (1%) 8136 (1%)
Dementia by ethnicity: (% of total study population ethnicity per year)
Māori 699 (1%) 741 (1%) 801 (1%) 867 (1%)
Pacific 279 (1%) 330 (1%) 351 (1%) 348 (1%)
European 12 057 (2%) 11 730 (2%) 12 225 (2%) 12 750 (2%)
Asian 321 (1%) 357 (1%) 411 (1%) 444 (1%)
MELAA 30 (1%) 27 (1%) 42 (1%) 51 (1%)
Other 36 (0.3%) 57 (0.4%) 75 (0.5%) 78 (0.5%)
Dementia by ethnicity, age and sex standardised (% of total study population ethnicity per year)
Maori 2% 2% 2% 2%
(Continues)
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the dispensing data set (Appendix S2). The mortality data set 
was only available for 2012 at the time of analysis due to 
temporal lag in public releases. Formulation codes identified 
anti-dementia drugs (Appendix S3). Only two anticholinest-
erases (donepezil and rivastigmine) are funded, rivastig-
mine only since 2014. Dementia sub-types were classed by 
ICD-10-AM codes obtained from hospital or mortality data 
(Appendix S4). Appendix S5 refers to information on the 
SAS code.
2.3 | Statistical analyses
Dementia cases were calculated by year, sub-type and 
geographical region. Released outputs were subject to 
statistical disclosure control in accordance with Statistics 
NZ, including random rounding to base 3 (RR3), where 
numbers are rounded to the nearest multiple of 3, to pro-
tect confidentially.15,16 For ethnic comparisons of demen-
tia rates, we used direct age-sex standardisation to take 
account of differences in age and sex profile between 
different ethnic groups. Age-sex standardised rates were 
calculated using 5-year age-sex groups and weights de-
rived from the total (all ethnicities) denominator popula-
tion described above.
2.4 | Ethics
Ethical approval was granted by The University of Auckland's 
Human Participant's Ethics Committee in April 2017 (refer-
ence 019125).
The study is reported according to RECORD (STROBE) 
guidelines.17
3 |  RESULTS
3.1 | Denominator cohorts from 2012-2015
Table  1 details the study's population: 891  558; 916  065; 
945 252; and 966 483 people for 2012-2015, respectively.
Study population—population ≥60 years in NZ per year 
(denominator group, population at risk) 2012 2013 2014 2015
Pacific 2% 2% 2% 2%
Euro 1% 1% 1% 1%
Asian 1% 1% 1% 1%
MELAA 2% 1% 2% 2%
Other 0.4% 1% 1% 1%
Dementia by age range: (% of total dementia cases per year)
60-64 267 (2%) 300 (2%) 312 (2%) 294 (2%)
65-69 582 (4%) 621 (5%) 705 (5%) 756 (5%)
70-74 1257 (9%) 1326 (10%) 1404 (10%) 1443 (10%)
75-79 2175 (16%) 2205 (17%) 2340 (17%) 2553 (18%)
80-84 3264 (24%) 3219 (24%) 3255 (24%) 3375 (23%)
85-89 3486 (25%) 3348 (25%) 3447 (25%) 3510 (24%)
90-94 1860 (14%) 1683 (13%) 1869 (14%) 1899 (13%)
95+ 618 (5%) 438 (3%) 465 (3%) 546 (4%)
Dementia by geographical area: (% of total dementia case per year)
North Island 9696 (71%) 9363 (71%) 9870 (72%) 10 197 (71%)
South Island 3702 (27%) 3492 (27%) 3570 (26%) 3810 (27%)
Note: In accordance with the journal style, percentages have been rounded up to the nearest whole number. Disparities in sum of counts: Mortality data were only 
available for 2012 at the time of analysis and so do not contribute to dementia counts for other years. Counts for dementia sub-type represent an ICD coding and not an 
individual (who may have more than one sub-type), so the totals differ from the total dementia cases (which also includes counts found from dementia drugs as stated 
in methods). Counts for ethnicity do not all add up as total response ethnicity coding is used in NZ where an individual can belong to more than one ethnic group.13 
Released outputs were subject to statistical disclosure control in accordance with Statistics Protocols, including suppressing counts <6, and random rounding to the 
base of three (RR3) to avoid identification.14
aSex and age missing 7956 (2012), 5880 (2013), 5931 (2014), 5931 (2015). 
bEthnicity was missing for 38 265 in the total study population. 
cGeographical information on Islands missing 24 315 (2012), 17 385 (2013), 17 781 (2014), 17 736 (2015). 
T A B L E  1  (Continued)
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3.1.1 | Dementia prevalence
Dementia cases were 13 677 (2012), 13 155 (2013), 13 800 
(2014) and 14 391 (2015)- 0.3% of NZ's total population in 
2015 and 2% of our cohort aged ≥60 years. Most were ‘un-
specified dementia’ sub-type; and around 9% had more than 
one dementia sub-type. Table  1 provides further details of 
dementia cases. The mean age for dementia ranged from 81.9 
to 82.5 years (SD 7.7-7.8). Most dementia was amongst the 
80-89 age groups (47%-49% of all dementia cases). However, 
in 2012 the ≥95 age group had a slightly higher proportion 
(5%), potentially reflecting the additional data set (mortality) 
present for this year.
Europeans were the largest ethnic group contributing most 
to the overall dementia counts (88%-89% of dementia cases). 
Māori with dementia contributed 5%-6% of dementia cases, 
whilst the Asian ethnic group contributed 2%-3% overall. This 
roughly reflects the prevalence of each ethnic group within the 
study population. Interestingly, when dementia cases were sep-
arated by ethnicity and calculated as a proportion of the ethnic 
group overall, the numbers differed less substantially (Europeans 
2% vs 1% of Māori, Table 1). However, following age and sex 
standardisation, the ethnic variation changed, with dementia 
cases higher for Māori than Non-Māori (2% vs 1%, Table 1).
Figure 1 identifies dementia ascertainment overlap be-
tween IDI data sources in 2012. From individual data sets, 
most cases were ascertained from ICD-10-AM codes in 
NMDS (n = 5751), followed by dispensing data (n = 4110). 
Of 33 030 people who died in 2012, 1167 (4%) had demen-
tia mentioned on death certificates (Figure 1). The remaining 
dementia cases were identifiable in more than one data set. 
However, only 120 dementia cases were found in all three 
data sets. In 2012, only 10% (n = 1335) were found in both 
NMDS and dispensing data sets and 8% (n  =  1128) were 
found in NMDS and mortality data. This highlights that mul-
tiple data sets are beneficial for ascertaining dementia.
Donepezil prescriptions contributed 5634 (41%), 6474 
(49%), 6843 (50%) and 7122 (49%) of dementia cases in 
2012-2015, respectively. Rivastigmine prescriptions only 
contributed 57 (0.4%) and 264 (2%) dementia cases in 2014-
2015, respectively (it was only publically available in NZ 
from 2014).
Given the population distribution, dementia was higher in 
North than South Island. The overall percentage of total de-
mentia remained relatively consistent across the years in both 
Islands (see Table 1).
4 |  DISCUSSION
Our study's purpose was to demonstrate the potential to es-
timate dementia prevalence using routinely collected data 
within NZ's national repository, the IDI. To our knowledge, 
this is the first to do this. Our reported dementia estimates 
were as follows: lower than those previously published for 
NZ at 48 182 and 62 287 in 2011 and 2016, respectively3,4; 
higher amongst Maori when results are age and sex standard-
ised; higher in the North than the South Island; and 9% had 
more than one dementia sub-type.
However, our estimates should be interpreted cautiously 
and might be considered as ‘lower bound’ estimates. Several 
explanations for these variations should be considered for 
future work. Currently, NZ estimates use countries’ data 
that may not be fully representative to NZ given it has pre-
viously been shown that significant intra-country variability 
in dementia rates exists.7,8 Alternatively, secondary care and 
mortality data can underestimate dementia counts, a well-es-
tablished issue with big data. Not everyone with dementia 
receives a diagnosis, is hospitalised, is prescribed anti-de-
mentia drugs or has dementia recorded on the death certif-
icate. Many people with dementia are managed in primary 
care, and without these records being part of the IDI, or in-
deed a national requirement to collect this diagnostic infor-
mation, the estimates may not include these people.
Unspecified dementia was the commonest sub-type. Around 
9% of individuals had more than one dementia diagnosis/sub-
type (Table 1). Without an agreed ICD coding for mixed de-
mentia, this is not unexpected. Whilst Alzheimer's remains the 
commonest diagnosed dementia, recent work identified un-
der-reporting of cerebrovascular pathology at postmortem.18 
This could be important for NZ if cerebrovascular pathology 
is higher amongst some ethnic groups.5 However, inter-ethnic 
sub-type variations in NZ may be minor.19
Dementia counts varied between the North and South 
Islands. Possible explanations include age and ethnicity dif-
ferences between North and South Islands; North Island sub-
stantially higher population (3/4 of NZ’s population lives in 
North Island); or the accessibility to memory clinics to obtain 
a diagnosis (only seven of the 20 District Health Boards in 
NZ have at least one memory clinic with 5 of these in North 
Island)20 Additionally, Non-Maori living in urban locations 
are more likely to be prescribed anti-dementia drugs.21 
Further work is required to understand factors influencing 
geographical variation in dementia.
Recording of dementia may be lower in ethnic minori-
ties.10 Despite representing 15% of NZ's population, Māori 
had 6% of total dementia cases in 2015. However, follow-
ing age and sex standardisation, Māori dementia was ap-
proximately 50% higher than Europeans'. Recent NZ studies 
highlight possible ethnic differences in diagnosis-seeking 
and earlier onset of dementia,19,22,23 potentially also influ-
enced by lower life expectancy.19,22,23 However, the LiLACS 
NZ study showed no significant difference in dementia rates 
between Māori and Non-Māori at an older age (>80 years) 
within a smaller cohort (937 people)5. Nonetheless, the atti-
tudes to dementia, including the stigma amongst indigenous 
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people, are importantly highlighted in a recent ADI report24, 
with a recent study discussing the complexities surrounding 
diagnosing mate wareware (dementia) in Māori communi-
ties.25 Further investigation, ideally within a national epide-
miological study of dementia, is warranted.
Population-based studies using big data have several lim-
itations. Of relevance is low diagnostic coverage for demen-
tia26 or the ‘diagnosis gap’, which comprises three important 
and inter-related dimensions: patients who have dementia 
but do not have it recorded as a diagnosis; those who have 
dementia but do not interact with health/social services; and 
patients who have cognitive impairment that impacts on daily 
function but may not receive a dementia-related diagnosis. 
In the UK, specific population studies have been used to es-
timate the ‘diagnosis gap’ and then extrapolated to the whole 
population to better inform health-care delivery.27
Further limitations include the types and reliability of data 
sets for ascertaining dementia in NZ's multi-ethnic popula-
tion. Neither memory clinic nor primary care consultation 
data are available within the IDI. Primary care consultation 
data inferring cognitive impairment and dementia would be a 
valuable addition to the IDI, as would memory clinic outpa-
tient data. Indeed, since our study, the IDI now incorporates 
the NZ InterRAI database (an extensive resource for under-
standing cognition, dementia and care needs of NZ's older 
people).28 This addition, along with including other data sets 
into the IDI, will allow validation of data sets for dementia 
coding and ascertainment specific to NZ and triangulation of 
dementia prevalence results to facilitate the delivery of NZ's 
Framework for Dementia Care.29
Wilkinson's recent systematic review showed dementia 
coding and positive predictive values (PPVs) varied widely, 
with <50% of dementia cases identified from routinely 
collected data and PPVs for dementia diagnoses ranging from 
33% to 100%.30 This is comparable with other studies,10-12,31-33 
one highlighting only 53% of known dementia patients had 
dementia recorded on their hospital discharge.34 However, 
some studies achieved PPVs of >80%-90% within routinely 
collected data, meaning that those with a dementia diagnosis 
recorded were likely to have the diagnosis of dementia.30
Within secondary care data, dementia ascertainment had 
higher sensitivity if hospital admissions and mortality data 
were combined, and lower sensitivity when only primary 
ICD codes were selected from death certificates.30 We miti-
gated for this by including ICD codes in any position on death 
certificates and combining hospital admissions and mortality 
data. Some recent studies have shown comparability of rou-
tinely collected hospital and primary care data for dementia 
ascertainment,11,12 highlighting good sensitivity and speci-
ficity compared with memory clinic data.10 Whilst there is no 
‘gold-standard’ data source, we attempted to overcome some 
of these limitations by including multiple data sets, as recom-
mended by recent systematic reviews.30,35
It is also important to recognise that routinely collected 
data will vary with time. For instance, rates may rise due to 
ageing populations, improved diagnosis, access to additional 
anti-dementia drugs (eg Rivastigmine in NZ in 2014) and 
awareness of dementia.
5 |  CONCLUSION
This study shows it is possible to ascertain dementia counts 
within the IDI and that these differ from current estimates. 
Traditional ‘gold-standard’ country-wide epidemiological 
studies are costly and labour-intensive, but the IDI could 
F I G U R E  1  Venn diagram of 
dementia ascertainment for dementia cases 
for 2012
Note : Released outputs were subject to statistical disclosure control in accordance with Statistics NZ protocols
The Integrated Data Infrastructure data sets are updated at different time points—the mortality data set was
only available for 2012 at the time of analysis due to temporal lag in its public releases
ICD-10-AM codes in 
publicly funded 
hospital discharges 
(NMDS) 
ICD-10-AM codes in mortality 
data (death certificates) 
Dispensing data  
(anti-dementia drug 
prescriptions) 
n = 5751n = 4110  n = 1335
 n = 120 n = 1128
n = 69 
n = 1167
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provide a future tool to enhance understanding of dementia 
prevalence in NZ at a national level. Our research highlights 
the need for further work including a national epidemio-
logical study of dementia using the InterRAI within the IDI, 
and adding further relevant data sets (memory clinics and 
primary care). This will also allow validation for dementia 
recording accuracy in NZ's routinely collected data sets, im-
prove dementia ascertainment; and understand the ‘diagnosis 
gap’ specific to NZ, and ultimately better inform health-care 
delivery.
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